As we have previously shown that the inhibitory effect of midostaurin can be further enhanced by additional SYK inhibition against mutant FLT3‐positive AML,22 we were particularly interested in investigating the synergizing potential of FLT3 and SYK inhibition in the context of mutant CBL‐positive leukaemia, given our observations. The gene discussed is FLT3; the disease is leukemia.